AU2698697A - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis

Info

Publication number: AU2698697A
Authority: AU; Australia
Prior art keywords: atherosclerosis; treatment; azetidinone derivatives; azetidinone; derivatives
Prior art date: 1996-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU26986/97A

Other languages

English (en)

Inventor

Dashyant Dhanak

Deirdre Mary Bernadette Hickey

Robert John Ife

Colin Andrew Leach

Colin Theobald

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

SmithKline Beecham Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-26

Filing date

1997-04-15

Publication date

1997-11-19

1996-04-26 Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en

1996-11-15 Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en

1996-12-03 Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en

1997-04-15 Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd

1997-11-19 Publication of AU2698697A publication Critical patent/AU2698697A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU26986/97A 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis Abandoned AU2698697A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GBGB9608646.7A GB9608646D0 (en)	1996-04-26	1996-04-26	Novel compounds
EP9608646		1996-04-26
GBGB9623756.5A GB9623756D0 (en)	1996-11-15	1996-11-15	Novel compounds
EP9623756		1996-11-15
EP9625121		1996-12-03
GBGB9625121.0A GB9625121D0 (en)	1996-12-03	1996-12-03	Novel compounds
PCT/EP1997/001898 WO1997041098A1 (en)	1996-04-26	1997-04-15	Azetidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number	Publication Date
AU2698697A true AU2698697A (en)	1997-11-19

Family

ID=27268259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU26986/97A Abandoned AU2698697A (en)	1996-04-26	1997-04-15	Azetidinone derivatives for the treatment of atherosclerosis

Country Status (17)

Country	Link
EP (1)	EP0915843A1 (es)
JP (1)	JP2000509049A (es)
AR (1)	AR006833A1 (es)
AU (1)	AU2698697A (es)
BR (1)	BR9709196A (es)
CA (1)	CA2252696A1 (es)
CZ (1)	CZ341098A3 (es)
HU (1)	HUP9901359A3 (es)
ID (1)	ID16660A (es)
IL (1)	IL126696A0 (es)
MA (1)	MA26426A1 (es)
NO (1)	NO984939L (es)
NZ (1)	NZ332476A (es)
PE (1)	PE64398A1 (es)
PL (1)	PL329530A1 (es)
TR (1)	TR199802160T2 (es)
WO (1)	WO1997041098A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE437862T1 (de)	2000-02-16	2009-08-15	Smithkline Beecham Plc	Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MEP27808A (en)	2001-01-26	2010-10-10	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE331512T1 (de)	2001-01-26	2006-07-15	Schering Corp	Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
CN1275949C (zh)	2001-03-28	2006-09-20	先灵公司	2－吖丁啶酮中间体化合物的对映体选择性合成
AR038956A1 (es) *	2001-05-25	2005-02-02	Schering Corp	Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es)	2003-03-07	2005-10-18	Schering Corp	Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en)	2003-03-07	2011-07-05	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en)	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8962633B2 (en)	2007-05-11	2015-02-24	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
WO2008140449A1 (en)	2007-05-11	2008-11-20	Thomas Jefferson University	Methods of treatment and prevention of neurodegenerative diseases and disorders
EP2155225B1 (en)	2007-05-11	2015-07-08	The Trustees of the University of Pennsylvania	Methods of treatment of skin ulcers
UY33766A (es)	2010-12-06	2012-06-29	Glaxo Group Ltd	COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
WO2012080497A2 (en)	2010-12-17	2012-06-21	Glaxo Group Limited	Methods of treatment and prevention of eye diseases
US20140171431A1 (en)	2011-06-27	2014-06-19	Jianhua Shen	Azole heterocyclic compound, preparation method, pharmaceutical composition and use
TW201321382A (zh)	2011-07-27	2013-06-01	Glaxo Group Ltd	化合物
WO2013013503A1 (en)	2011-07-27	2013-01-31	Glaxo Group Limited	2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
PE20151251A1 (es)	2013-01-25	2015-09-10	Glaxosmithkline Ip Dev Ltd	Derivados [5,6] biciclicos de imidazo pirimidona con actividad sobre enzimas lp-pla2
AU2014210259B2 (en)	2013-01-25	2016-11-03	Glaxosmithkline Intellectual Property Development Limited	Compounds
WO2014114249A1 (en)	2013-01-25	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Bicyclic pyrimidone compounds as inhibitors of lp-pla2
WO2016012917A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
EP4056571A4 (en)	2019-11-09	2024-01-24	Shanghai Simr Biotechnology Co., Ltd.	TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN115304620A (zh)	2021-05-07	2022-11-08	上海赛默罗生物科技有限公司	嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4680391A (en) *	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) *	1988-04-11	1989-12-15	Merck & Co Inc	Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) *	1990-10-15	1992-08-18	Merck & Co Inc	Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) *	1991-06-25	1993-01-07	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL102582A0 (en) *	1991-07-23	1993-01-14	Schering Corp	Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
CA2108584C (en) *	1992-10-27	1998-11-24	James B. Doherty	Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) *	1992-12-17	1994-06-23	Merck & Co., Inc.	New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0658205B1 (en) *	1993-06-25	2000-03-15	Smithkline Beecham Plc	Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
DE69434609T2 (de) *	1993-10-06	2006-09-21	Icos Corp., Bothell	Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) *	1994-10-29	1994-12-14	Smithkline Beecham Plc	Novel compounds
MA23834A1 (fr) *	1994-12-22	1996-10-01	Smithkline Beecham Plc	Procede de preparation de composes inhibiteurs de l'enzyme lp-pla2 et de compositions pharmaceutiques les contenant
WO1996029307A1 (en) *	1995-03-23	1996-09-26	Japan Tobacco Inc.	Diphenylmethyl-azetidinone compounds and elastase inhibitor
TR199701762T1 (xx) *	1995-07-01	1998-05-21	Smithkline Beecham P.L.C.	Damar t�kanmas� tedavisi i�in azetidinon t�revleri.
WO1997021676A1 (en) *	1995-12-08	1997-06-19	Smithkline Beecham Plc	Azetidinone compounds for the treatment of atherosclerosis

1997
- 1997-04-15 IL IL12669697A patent/IL126696A0/xx unknown
- 1997-04-15 CA CA002252696A patent/CA2252696A1/en not_active Abandoned
- 1997-04-15 HU HU9901359A patent/HUP9901359A3/hu unknown
- 1997-04-15 CZ CZ983410A patent/CZ341098A3/cs unknown
- 1997-04-15 WO PCT/EP1997/001898 patent/WO1997041098A1/en not_active Ceased
- 1997-04-15 JP JP9538507A patent/JP2000509049A/ja active Pending
- 1997-04-15 TR TR1998/02160T patent/TR199802160T2/xx unknown
- 1997-04-15 AU AU26986/97A patent/AU2698697A/en not_active Abandoned
- 1997-04-15 PL PL97329530A patent/PL329530A1/xx unknown
- 1997-04-15 BR BR9709196A patent/BR9709196A/pt not_active Application Discontinuation
- 1997-04-15 EP EP97920699A patent/EP0915843A1/en not_active Withdrawn
- 1997-04-15 NZ NZ332476A patent/NZ332476A/en unknown
- 1997-04-24 PE PE1997000311A patent/PE64398A1/es not_active Application Discontinuation
- 1997-04-24 AR ARP970101682A patent/AR006833A1/es unknown
- 1997-04-24 MA MA24565A patent/MA26426A1/fr unknown
- 1997-04-25 ID IDP971394A patent/ID16660A/id unknown
1998
- 1998-10-23 NO NO984939A patent/NO984939L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO984939L (no)	1998-12-23
HUP9901359A2 (hu)	1999-08-30
MA26426A1 (fr)	2004-12-20
BR9709196A (pt)	1999-05-25
HUP9901359A3 (en)	2000-03-28
PE64398A1 (es)	1999-01-06
NZ332476A (en)	2000-06-23
CZ341098A3 (cs)	1999-03-17
JP2000509049A (ja)	2000-07-18
NO984939D0 (no)	1998-10-23
CA2252696A1 (en)	1997-11-06
AR006833A1 (es)	1999-09-29
WO1997041098A1 (en)	1997-11-06
EP0915843A1 (en)	1999-05-19
IL126696A0 (en)	1999-08-17
PL329530A1 (en)	1999-03-29
TR199802160T2 (xx)	1999-04-21
ID16660A (id)	1997-10-30

Publication	Publication Date	Title
AU2698697A (en)	1997-11-19	Azetidinone derivatives for the treatment of atherosclerosis
AU3869895A (en)	1996-05-23	Azetidinone derivatives for the treatment of atherosclerosis
AU4389896A (en)	1996-07-10	Substituted azetidin-2-ones for treatment of atherosclerosis
AU1735497A (en)	1997-09-10	Sulfonylureidopyrazole derivatives
AU6305096A (en)	1997-02-05	Azetidinone derivatives for the treatment of atherosclerosis
AU3867997A (en)	1998-03-19	Chromene-3-carboxylate derivatives
AU3011397A (en)	1997-11-26	Water-stabilized organosilane compounds and methods for using the same
AU2956097A (en)	1997-12-05	Alkylaminobenzothiazole and -benzoxazole derivatives
EP1008579A3 (en)	2003-01-29	Cyclopentenebutanol derivatives
AUPP069497A0 (en)	1998-01-08	Curtain assembly for waste treatment
AU4962097A (en)	1998-05-22	2-methoxyphenylpiperazine derivatives
AU2961097A (en)	1998-01-05	Substituted pyrazolylpyrazole derivatives
AU1793197A (en)	1997-09-10	Pyrazole-4-yl-hetaroyl derivatives
AU3685097A (en)	1998-03-12	N-benzylazolium derivatives
AU1600297A (en)	1997-09-02	Aryl derivatives
AU3473193A (en)	1993-08-03	Treatment for atherosclerosis
AU4941796A (en)	1996-09-18	Use of moxonidine for the treatment of atherosclerosis
HK1020048A (en)	2000-03-10	Azetidinone derivatives for the treatment of atherosclerosis
AU2123797A (en)	1997-09-22	2-thioxotetrahydropyrimidin-4-one derivatives
AU7873198A (en)	1998-07-17	Polysaccharide-peptide derivatives
AU1558497A (en)	1997-08-28	Micacocidin derivatives
HK1002277A (en)	1998-08-14	Azetidinone derivatives for the treatment of atherosclerosis
HK1010875A (en)	1999-07-02	Azetidinone derivatives for the treatment of atherosclerosis
AU3817899A (en)	1999-11-01	Therapy of atherosclerosis
AU4134597A (en)	1998-03-26	Dc-89 derivatives

Legal Events

Date	Code	Title	Description
2000-12-07	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted